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Abstract
Chronic lymphocytic leukaemia (CLL) is the most common B-cell malignancy with a variable clinical outcome.
Biomarkers of CLL progression are required for optimising prognosis and therapy. The Inhibitor of Bruton’s tyrosine
kinase—isoform α (IBTKα) gene encodes a substrate receptor of Cullin 3-dependent E3 ubiquitin ligase, and promotes
cell survival in response to the reticulum stress. Searching for novel markers of CLL progression, we analysed the
expression of IBTKα in the peripheral blood B-cells of CLL patients, before and after ﬁrst line therapy causing remission.
The expression of IBTKα was signiﬁcantly increased in disease progression, and decreased in remission after
chemotherapy. Consistently with a pro-survival action, RNA interference of IBTKα increased the spontaneous and
Fludarabine-induced apoptosis of MEC-1 CLL cells, and impaired the cell cycle of DeFew B-lymphoma cells by
promoting the arrest in G0/G1 phase and apoptosis. Consistently, RNA interference of IBTKα up regulated the
expression of pro-apoptotic genes, including TNF, CRADD, CASP7, BNIP3 and BIRC3. Our results indicate that IBTKα is a
novel marker of CLL progression promoting cell growth and resistance to apoptosis. In this view, IBTKα may represent
an attractive cancer drug target for counteracting the therapy-resistance of tumour cells.
Introduction
Chronic lymphocytic leukaemia (CLL) is the most
common adult leukaemia in Western countries with an
incidence of 4.6 per 100,000 new cases per year (http://
www.who.int/selection_medicines/committees/expert/20/
applications/CLL.pdf). It is diagnosed by routine blood test
showing monoclonal B-lymphocytosis that is typically
CD5+1 and persists for more than 3 months with pro-
gressive accumulation of tumour B-cells in bone marrow
and lymphoid tissues. CLL patients may present a stably
asymptomatic disease without requiring any treatment in
their lifetime, or may suffer of rapid disease progression
with poor outcome. Sequencing of immunoglobulin heavy
chain variable sequence (IGHV) of B-cell receptor (BCR)
classiﬁes CLL in mutated (M-CLL) and unmutated
(U-CLL) subtypes, depending on more or less than 2%
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mutations compared to germline1,2. U-CLL and M-CLL
origin from pre-germinal centre (GC) or post-GC CD5+
B-cells, respectively, being U-CLL the less common (1%)
subtype3. IGHV-based classiﬁcation has been used for
predicting the clinical course of disease, as U-CLL is
associated with poorer outcome compared to M-CLL.
However, emerging evidence indicates that prognosis
cannot be restricted to the IGVH mutation status, and
great effort is still required for identifying molecular
markers of disease progression. The enhanced expression
of CD38, Lipoprotein lipase (LPL) and Zeta-chain-
associated protein kinase 70 (ZAP70) was associated to
U-CLL with rapid fatal outcome4–7. Nevertheless, these
genes were not proved to be reliable biomarkers for
evaluating the clinical course of CLL and the effectiveness
of therapy.
The Inhibitor of Bruton’s tyrosine kinase (IBTK) gene
maps at 6q14.1 chromosomal region8,9, proximally to the
6q deletion hotspots of CLL10–12. Deletions in the IBTK
genomic region occur in Richter’s Transformation of CLL
to relapsed diffuse large B-cell lymphoma (DLBCL), a very
aggressive form of non-Hodgkin lymphoma (NHL)13. The
IBTK gene encodes the proteins isoforms IBtkα, IBtkβ and
IBtkγ and the pre-miR-IBTK39,14. The 26 kDa IBtkγ
protein was originally characterised as an inhibitor of
Bruton’s tyrosine kinase (Btk)8,15, an essential enzyme for
BCR signalling. The 150 kDa IBtkα protein is the most
abundant isoform that is highly expressed in B-lymphoid
tissues9,16. It acts as substrate receptor of the Cullin 3-
dependent E3 ligase, and promotes the K-48 ubiquitina-
tion coupled to proteasomal degradation of Pdcd4, a
translation inhibitor, resulting in the increased cap-
dependent and independent translation16. RNA inter-
ference of IBTKα affected the wide genome expression
and RNA splicing in HeLa and K562 cells in cell-type
speciﬁc manner17. Collectively, these ﬁndings indicate
that IBtkα has pleiotropic effects in protein synthesis/
turnover and RNA metabolism.
There is evidence that IBtkα is involved in cell survival
and tumour growth. In fact, RNA interference of IBTKα
reduced the viability of DLD-1 K-Ras-positive colorectal
cancer cells18. Further, the exposure to the industrial
pollutant titanium dioxide increased the production of
IBtkα in human bronchial epithelial cells19. Thapsigargin
and tunicamycin, two inducers of endoplasmic reticulum
stress, also increased the expression of IBtkα in HeLa
cells, and this event was required for cell survival20. Being
highly expressed in B-lymphoid tissues, IBtkα could sus-
tain B-cell survival, and eventually be involved in B-
tumorigenesis when up regulated. Consistently with this
hypothesis, differential methylation of the IBTK genomic
region was reported for U-CLL and M-CLL, suggesting a
possible correlation between the IBTKα expression level
and aggressiveness of disease21.
Results
The expression of IBTKα is up regulated in CLL progression
This study was aimed to analyse the expression of
IBTKα in B-lymphocytes of CLL patients at different
stages of disease, before and after ﬁrst line therapy. Total
RNA of CD19+ B-cells was analysed by Real-time PCR for
the expression of IBTKα and some markers of CLL
aggressiveness, including LPL, CD38 or ZAP70 genes
(Supplementary Table 2). The expression of IBTKα gene
progressively increased in Binet A (p= 0.0005), Binet B (p
< 0.0001) and Binet C (p< 0.0001) groups compared to
healthy donors, with the highest expression in Binet C
group (Fig. 1a). No difference of IBTKα expression was
observed between healthy donors and patients after
therapy causing remission of disease (Fig. 1a). In the same
samples, no signiﬁcant differences in expression levels of
LPL, CD38 and ZAP70 were observed between healthy
donors and CLL groups (Figs. 1b–d). These genes were
previously reported to be up regulated in the U-CLL
subtype with the poorest outcome4–7. Based on IGHV
sequencing22, ten CLL patients with the highest IBTKα
expression (CLL 2, 3, 4, 5, 11, 14, 22, 25, 26, 31) belonged
to the M-CLL subtype, which might explain the lack of
up-regulation of LPL, CD38 and ZAP70 genes in our CLL
samples. In the group of patients in therapy with remis-
sion, the expression of IBTKα dropped to the healthy
control level (Fig. 1a), indicating that the hyper-
expression of IBTKα was associated with the presence of
tumour cells.
IBtkα is a substrate receptor of Cul3-dependent E3
ubiquitin ligase and undergoes K48-ubiquitination cou-
pled to proteasomal degradation16. Thus, we evaluated
whether the IBtkα protein level correlated with the
increased IBTKα RNA expression in CLL samples. To this
end, B-cell extracts of twelve randomly chosen CLL
patients were analysed by Western blotting for the con-
tent of IBtkα protein. Compared to healthy donors, the
IBtkα protein signiﬁcantly increased in 3 out of 6 Binet A
patients, 5 out of 5 Binet B patients, and 2 out of 2 Binet C
patients (Fig. 1e), indicating a parallel increase in both
IBTKα RNA and protein levels in most of CLL patients
(compare Fig. 1e and Supplementary Figure 2). The lim-
iting amount of CLL cells did not allow extending the
Western blotting analysis of IBtkα protein to other
patients. To overcome this problem, we developed an
intracellular ﬂow cytometry protocol for staining IBtkα
with a speciﬁc antibody. We conﬁrmed that the content of
IBtkα protein progressively increased in three CLL
patients of Binet stage A (CLL13), B (CLL20) and C
(CLL46) with the aggressiveness of disease (Supplemen-
tary Figure 3).
In one patient (CLL11 of Binet B group) undergoing
ﬁrst line therapy, we could analyse both IBTKα gene and
protein expression before and after treatment with
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Rituximab and Bendamustine. A strong reduction of
IBTKα transcripts (about 100-folds, p= 0.0018) and IBtkα
protein was observed after therapy causing remission
(Figs. 1f, g). Even though this analysis was restricted to
one single patient, it provides additional evidence that
IBtkα is a tumour-associated marker and could be a
measure of effectiveness of therapy.
Lack of IBTKα sensitises CLL cells to spontaneous and
ﬂudarabine-induced apoptosis
The purine analogue Fludarabine (FAMP) is among the
most effective chemotherapeutic agents for ﬁrst-line and
second-line treatment of CLL23. FAMP-resistance occa-
sionally occurred in tumour cells24. To address the
question whether IBtkα was involved in mechanisms of
FAMP-resistance, we analysed the effect of IBTKα RNA
interference on FAMP-sensitivity of MEC-1, a CLL-
derived cell line peculiarly resistant to apoptosis induced
by chemotherapeutic agents25. We ﬁrst transduced MEC-
1 cells with lentiviral particles expressing shIBTKα or
shCTRL together with Green Fluorescent Protein (GFP),
for monitoring cell transduction efﬁciency. Forty eight-
hours post-transduction, MEC-1 cells were left untreated
or treated with 25 or 50 µM FAMP for 72 h, within a dose
range lower than 100 µM inducing apoptosis26. After
treatment, GFP-positive cells were analysed by FACS for
the binding of Annexin V-APC as measure of apoptosis.
RNA interference by shIBTKα caused 3-folds increase in
apoptosis compared to shCTRL (18.1% apoptosis in
shIBTKα compared to 5.99% in shCTRL; p= 0.0043)
(Figs. 2a, b). A similar increase in apoptosis was observed
in absence of IBTKα when cells were treated with lower
FAMP concentration (25 µM) (38.1% apoptosis in
shIBTKα compared to 10.9% in shCTRL) (Fig. 2c, d;
p= 0.0002), and higher FAMP concentration (50 µM)
(43% apoptosis in shIBTKα compared to 13.3% in shCTRL
(Fig. 2e, f; p= 0.0001). These results collectively indicated
that the lack of IBtkα sensitised MEC-1 cells to apoptosis,
with or without FAMP treatment, suggesting that IBtkα
inhibition could improve the efﬁcacy of chemotherapy.
IBTKα RNA interference impairs the cell growth by
increasing G0/G1 and apoptotic cells of cell cycle and up
regulating the expression of pro-apoptotic genes
Previous reports indicated that IBtkα was involved in
the cellular stress response18–20. To get further insights
into the pro-survival role of IBtkα, the IBTKα gene was
silenced in DeFew cells by RNA interference with lenti-
viral transduction of shIBTKα or shCTRL (Supplementary
Figure 4), and the cell growth was analysed by resazurin-
based colorimetric assay. Cells silenced for IBTKα had a
doubled replication time compared to unsilenced cells
(Fig. 3a). To understand whether the slower growth of
IBTKα-silenced cells was due to delay in cell replication or
increase in cell death, we analysed the cell cycle using
Propidium Iodide staining. As compared to shCTRL, the
number of shIBTKα-transduced DeFew cells was sig-
niﬁcantly reduced in S-phase (from 40 to 20%; p= 0.004),
and increased in G0/G1 population (from 38 to 57%;
p= 0.02) and subG1 population (from 2 to 10%; p=
0.005) (Fig. 3b). These data indicate that lack of IBTKα
caused a partial block of the cell cycle in G0/G1 phase
together with the increase of apoptotic cells.
To address the molecular mechanisms of IBtkα-
dependent cell survival, we analysed DeFew cells for the
expression of 84 genes involved in apoptosis (Supple-
mentary Table 3), with and without IBTKα RNA inter-
ference. TNFα and four pro-apoptotic genes of TNFα and
NFκB signalling (CRADD, CASP7, BNIP3 and BIRC3)
were signiﬁcantly up regulated in absence of IBtkα
(Fig. 4a). These results suggested that IBtkα likely inhib-
ited the expression of pro-apoptotic genes, including
TNFα. To test this hypothesis, we measured the expres-
sion of IBTKα and TNFα genes by Real-Time PCR of total
RNA extracted from CLL cells of representative patients
of Binet A, B and C stages. A progressive decrease of
TNFα expression was observed in the clinical course
of disease, concomitantly with the increased expression of
IBTKα (Fig. 4b). This observation was consistent with
TNFα up regulation in IBTKα-silenced DeFew cells
(Fig. 4a). Altogether these results suggest that IBTKα
(see ﬁgure on previous page)
Fig. 1 Expression of IBTKα, LPL, CD38 and ZAP70 in CLL patients. . a–d B-cells were isolated from healthy donors (HD), and CLL patients of Binet
A, B, C and In-Therapy groups. Total RNA was analysed by RT-qPCR for the expression of IBTKα a, CD38 b, ZAP70 c, and LPL d. β-ACTIN expression was
measured for normalisation. Statistical analysis was performed using Mann–Whitney test (GraphPad Prism 6). e Protein extracts from healthy donors
(HD) and CLL patients of Binet A (CLL9, 13, 16, 21, 29, 33), Binet B (CLL3, 6, 20, 37) and Binet C (CLL30, 46) stages. Proteins were separated by 4-12%
NuPAGE Novex Gels (ThermoFisher Scientiﬁc) and analysed by Western blotting with antibodies against IBtkα (ThermoFisher Scientiﬁc #PA5-24224)
and β-actin (Cell Signalling #3700S). f IBTKα gene expression in CLL11 patient before and after ﬁrst line therapy with Rituximab and Bendamustine.
Total RNA was analysed by RT-qPCR. Mean values (n = 3) ± SE are shown. Statistical analysis was performed using Unpaired t-test with Welch’s
correction (GraphPad Prism 6). g IBtkα protein content in CLL11 patient before and after ﬁrst line therapy with Rituximab and Bendamustine. Protein
extracts were analysed by Western blotting with antibodies against IBtkα (ThermoFisher Scientiﬁc #PA5-24224) and β-actin (Cell Signalling #3700 S). n.
s. indicates non-speciﬁc bands
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could promote tumour survival by inhibiting the expres-
sion of pro-apoptotic genes.
Discussion
This study provides the ﬁrst evidence of IBtkα as
prognostic marker of CLL progression. Our conclusions
are based on the analysis of IBTKα expression in three
independent groups of CLL patients that were stratiﬁed
according to the Binet staging system. One additional
group included CLL patients with disease remission after
ﬁrst line therapy. The main objectives were: (a) to deter-
mine whether the IBTKα expression was modulated in the
Fig. 2 IBTKα RNA interference increases spontaneous and ﬂudarabine–induced apoptosis in MEC-1 CLL cells. MEC-1 cells were transduced
with TurboGFP-shCTRL or TurboGFP-shIBTKα (Sigma-Aldrich), and after 5 days were left untreated (N.T.) a, b or 72 h-treated with Fludarabine at 25 µM
c and d or 50 µM e, f. Then, cells were collected, stained with Annexin-V-APC and analysed by ﬂow cytometry. Binding of Annexin-V-APC was
measured for GFP-positive cells, as positive control of transduction. A representative experiment of three independent experiments is shown.
Statistically signiﬁcant differences were assessed using Mann–Whitney test (GraphPad Prism 6), as follows: a vs. b p = 0.0043; c vs. d p = 0.0002; e vs.
f p = 0.0001
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clinical course of disease and after ﬁrst therapy; (b) to
compare IBTKα to prognostic markers of CLL, including
CD38, LPL and ZAP70 genes; (c) to unveil the potential
role of IBTKα in CLL progression.
We observed that the IBTKα expression was increased
in CLL cells concomitantly with the progression of the
disease. Conversely, the expression of IBTKα diminished
in patients after ﬁrst therapy, jumping to the levels of
healthy donors. In the same CLL samples, the expression
of CD38, LPL and ZAP70 genes was similar to healthy
donors. In previous reports the enhanced expression of
CD38, LPL and ZAP70 was reported in U-CLL with the
poorest outcome4–7. In our study, we randomly enroled
CLL patients independently of the IGHV mutational sta-
tus. However, according to IGHV genetic analysis, CLL
patients with the highest IBTKα expression and advanced
stage of disease were M-CLL, which could explain the
differences between our data and previous reports. We
also investigated the IBTKα expression in the same
patient before and after ﬁrst line therapy with Rituximab
and Bendamustine. This patient was M-CLL subtype
enroled at a very aggressive stage of disease. First line
therapy caused the remission of disease, as monitored by
clinical analysis and cytoﬂuorimetry. In this patient,
IBTKα was hyper-expressed in peripheral blood B cells
before therapy, while it was down regulated after therapy.
Based on this evidence, IBTKα was a sensitive marker of
CLL progression and response to therapy.
CLL pathogenesis initiates with the proliferation of
precursor B-cells in bone marrow followed by their
expansion, clonal selection and transformation in lymph
nodes. The correlation between IBTKα expression and
Fig. 3 IBTKα RNA interference impairs the B-cell growth.
a The growth of DeFew cells, with or without IBTKα RNA interference,
was measured by resazurin-based colorimetric assay. Mean values
(n = 5) ± SE are shown. Doubling time was about 40 h for shIBTKα-
transduced cells compared to 24 h for shCTRL-transduced cells.
Statistical signiﬁcance was determined using the Holm-Sidak method,
with alpha = 5.000%. Each row was analysed individually, without
assuming a consistent SD (GraphPad Prism 6). The asterisk indicates
statistical signiﬁcance as follows: at 8 h p = 0,0167; at 12 h p = 0.005; at
24 h p = 0.0016; at 48 h p = 0.0037. b Cell cycle of DeFew, with or
without IBTKα RNA interference, was analysed by Propidium Iodide
staining. Mean values (n = 3) ± SE are shown. Statistical analysis was
performed using Unpaired t-test with Welch’s correction (GraphPad
Prism 6)
Fig. 4 IBTKα expression inversely correlates with TNFα
expression in the CLL progression. a DeFew cells were transduced
with shCTRL or shIBTKα, and after 5 days the total RNA was analysed
by RT-qPCR, using RT2 Proﬁler PCR Array-Human Apoptosis (Qiagen)
Values (mean ± SE, n = 3) are shown. Mean of ACTB, B2M and GAPDH
expression was used for normalisation. b B-cells were isolated from
healthy donors (HD), and representative patients of Binet A (CLL47), B
(CLL43) and Binet C (CLL52) stages. Total RNA was analysed for the
expression of IBTKα and TNFα by RT-qPCR. β-ACTIN expression was
measured for normalisation. Statistical analysis was performed using
Mann-Whitney test (GraphPad Prism 6). Mean values (n = 3) ± SE are
shown
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tumour aggressiveness suggests a pro-tumorigenic func-
tion of the IBtkα protein. It is not clear whether the
deregulated expression of IBTKα contributes to CLL
pathogenesis or it is a consequence of altered pathways in
B-tumorigenesis. Previous reports indicated that IBTKα
RNA interference caused the loss of viability and apop-
tosis of K-Ras-positive colorectal cancer cells18 and HeLa
cells exposed to endoplasmic reticulum stress20, sup-
porting a pro-survival action of IBtkα. Based on the
hypothesis that IBtkα could be required for CLL growth
and survival, we analysed B-cells viability in presence or
absence of IBTKα using RNA interference. In DeFew cells,
we showed that IBTKα silencing delayed the growth
kinetic, by arresting the cells in G0/G1 phase of cell cycle
and increasing the number of apoptotic cells. We won-
dered whether RNA interference of IBTKα could sensitise
B-cells to drug-induced apoptosis. Indeed, the lack of
IBtkα enhanced both the spontaneous and Fludarabine-
induced apoptosis of MEC-1, a CLL-derived cell line
peculiarly resistant to apoptosis25,26.
We previously reported that IBTKα RNA interference
affected the whole genome expression and RNA splicing
of several genes in K562 and HeLa cells17. Thus, we
addressed the question whether IBtkα could regulate the
expression of death-related genes in the B-cell context. To
this end, we analysed the expression of 84 genes involved
in apoptosis, in presence and absence of IBtkα. In DeFew
cells, RNA interference of IBTKα caused the up-
regulation of TNF, CRADD, CASP7, BNIP3 and BIRC3.
The comparative analysis of representative number of
CLL patients of Binet A, B and C stages and healthy
donors revealed that the increased expression of IBTKα
correlated with the decreased expression of TNFα in CLL
progression, which was consistent with the enhanced
expression of TNFα in DeFew cells upon IBTKα RNA
interference.
The ﬁve genes deregulated by IBtkα at the transcrip-
tional levels are linked to the TNFα and NF-κB signalling,
which is relevant for B-cell survival and proliferation.
CRADD and CASP7 act in TNFα signalling leading to
apoptosis through the activation of a cell death signal
transduction complex. In particular, CRADD is a protein
containing a death domain recruiting Caspase 2 to
membrane receptors for death signalling, such as the
tumour necrosis factor receptor 127. CASP7 is an indu-
cible caspase by the TNFα receptosomes28,29, whose
activity was increased in HeLa cells by IBTKα RNA
interference20. Since TNFα, CRADD and CASP7 share
the same pro-apoptotic pathway and are commonly up
regulated in absence of IBTKα, it is feasible that, con-
versely, the enhanced expression of IBTKα in CLL cells
could down regulate the expression of these pro-apoptotic
genes, thus counteracting apoptosis. Accordingly with this
hypothesis, we found that the down-regulation of TNFα
expression correlated with the up regulation of IBTKα
expression in the clinical course of disease. BNIP3 and
BIRC3, the other two up-regulated genes by IBTKα RNA
interference, are tumour suppressors. In particular, BNIP3
is a prognostic marker of breast cancer, whose deﬁciency
was associated with progression to metastasis in certain
cancer sub-types30. BIRC3 is a repressor of the non-
canonical NF-κB signalling, whose inactivation by
mutations occurred in a signiﬁcant number of FAMP-
refractory CLL31,32. Again, the increased expression of
BNIP3 and BIRC3 by IBTKα RNA interference in DeFew
cells suggests that IBTKα, when hyper-expressed in CLL,
could down-regulate the expression of these tumour
suppressor genes. Altogether, our results support a
pro-survival action of IBtkα through the transcriptional
inhibition of pro-apoptotic genes. At this time, it is
unclear how IBtkα exactly contributes to the deregulation
of apoptotic genes, and further efforts are needed to
undercover molecular partners of IBtkα in cancer cells. In
this regard, we have previously shown that the IBtkα
protein is substrate receptor of Cullin 3-dependent E3
ligase complex and promotes the ubiquitination coupled
to proteasomal degradation of the translation repressor
Pdcd416. The complexity of IBtkα interactome requires
further investigation to characterise other putative targets
of IBtkα for degradation16. It is reasonable to hypothesise
that IBtkα could affect both transcriptome and proteome
at least by affecting the stability of transcriptional and
translational activator and repressors.
The strict correlation between the IBTKα expression
and CLL progression indicates that the transcriptional
control of IBTKα is progressively switched on in the
clinical course of disease by not yet identiﬁed molecular
events. Such epigenetic event could be a part of
mechanisms to enrich tumour cells with functions giving
a survival advantage. Searching for transcriptional factors
activating the IBTKα gene in CLL could be relevant to
determine the signalling pathways that promote the
disease progression. In this context, the development of
inhibitors of IBtkα could increase the efﬁcacy of the
chemotherapeutic treatment in refractory patients.
Materials and methods
Peripheral blood samples
Peripheral blood samples of CLL patients (n= 56) were
randomly collected at the Haematology Unit of the
Department of Clinical Medicine, University “Federico II”
of Naples. Peripheral blood samples of healthy donors
(HD, n= 30) were collected at the Transfusional Centre,
University “Federico II” of Naples. All donors gave
informed consensus before the sampling. CLL patients
were diagnosed by immunophenotyping of peripheral
B-lymphocytes (CD5+, CD19+, CD23+) and clinical
examinations, and classiﬁed according to the Binet staging
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system33. Molecular and clinical data of CLL are sum-
marised in Supplementary Table 1. CLL were grouped as
follows: Binet A (n= 26); Binet B (n= 12); Binet C
(n= 5). An additional group included in-therapy patients
(n= 13) of the Binet A, B or C stages, which underwent
ﬁrst line therapy, and showed remission of disease at the
time of blood collection based on clinical and haemato-
logical parameters, independently of the therapeutic
protocols.
CD19+ B-cells were isolated by negative selection from
whole blood using RosetteSep Human B Cell Enrichment
Cocktail (Stem Cell Technology), as previously descri-
bed22, and represented 95% cell population as measured
by ﬂow cytometry (Supplementary Figure 1). The IGHV
regions of ten CLL samples with the highest expression of
IBTKα were sequenced to determine the mutation level
compared to germline, as previously described22; these
samples carried more than 2% mutations within the IGHV
region, and thus were deﬁned M-CLL.
Cells, plasmids, and RNA interference
HEK293T cells were purchased from American Type
Culture Collection (Manassas, VA, U.S.A.) and grown in
DMEM (Gibco, Invitrogen, Carlsbad, CA) supplemented
with 10% heat-inactivated FBS, 2 mM L-glutamine,
100 U/ml penicillin, and 100 μg/ml streptomycin (Gibco).
HEK293T cells were used as packaging cells for the pro-
duction of lentiviral particles containing shRNA. DeFew
cells, an EBV-negative B-lymphoma cell line34,35, were
grown in RPMI 1640 (Gibco) supplemented with 10%
heat-inactivated FBS, 2 mM L-glutamine, 100 U/ml peni-
cillin, and 100 μg/ml streptomycin (Gibco). MEC-1 cells, a
B-CLL cell line25, were purchased from DSMZ (Leibniz,
Germany) and were grown in IMDM (Gibco) supple-
mented with 10% heat-inactivated FBS, 2 mM L-gluta-
mine, 100 U/ml penicillin, and 100 µg/ml streptomycin
(Gibco). The plasmids pCMV-dR8.91 and pCMV-VSVG
were purchased from AddGene (OneKendall, Cambridge,
MA, USA). The lentiviral constructs expressing the
IBTKα-shRNA (TRCN0000082575) or control shRNA
(SHC002) were purchased from MISSION (Sigma
Aldrich, St. Louis, MO, USA). The TurboGFP™ version
of the IBTKα-shRNA and control shRNA vectors carries
the lentiviral backbone of vector pLKO.1-puro expressing
the TurboGFP gene under the CMV promoter to monitor
the transduction efﬁciency by optical microscopy. The
IBTKα-shRNA targets the nucleotide sequence from
+1534 to +1552 of the IBTKα transcript (Ensemble
Reference Sequence: ENST00000306270). Lentiviral par-
ticles expressing IBTKα shRNA or control shRNA were
produced by transfection of HEK293T cells17. Brieﬂy,
HEK293T cells (2× 106) were transfected with pCMV-
dR8.91 (3,5 μg) and pCMV-VSVG (0,7 μg) together with
IBTKα-shRNA (7 μg), or control-shRNA (7 μg); 48-h
post-transfection, cell supernatant was collected.
Enzyme-linked immunosorbent assay (ELISA) using anti-
p24 antibody measured virions concentration. DeFew or
MEC-1 cells (1× 106) were infected with viral stocks
(500 ng of p24) by spinoculation, as previously descri-
bed17. To select cell clones stably expressing IBTKα-
shRNA or control-shRNA, puromycin (2 μg/mL) was
added to cell cultures 48 h after infection, when indicated.
Real-time PCR
Total RNA was extracted from cells using TRIzol
reagent (Thermo Fisher Scientiﬁc) according to manu-
facturer’s protocol. RNA quality was checked by electro-
phoresis of 1 µg of samples on MOPS-agarose gel. Aliquots
(3 µg) of total RNA were subjected to DNase I digestion
(Thermo Fisher Scientiﬁc) and reverse transcribed using
SSIV Reverse Transcriptase (Thermo Fisher Scientiﬁc)
following manufacturer’s instructions. Real-Time PCR was
performed with the PowerUP Sybr green master mix
(Thermo Fisher Scientiﬁc) using a Quant Studio 7 Flex
instrument and Fast gene-expression method: 95 °C, 20”;
(95 °C, 1”; 60 °C, 20”)× 40 cycles; 95 °C, 15”; 60 °C 1’; 0.05 °
C/s up to 95 °C. Real-Time data were analysed using
Quant Studio Real-Time PCR Software (Thermo Fisher
Scientiﬁc). Reactions were carried out in triplicate, and
gene expression levels were calculated relatively to β-Actin
mRNA levels as endogenous control. Real-Time PCR
ampliﬁcation values were reported as 2−ΔCt, were ΔCt is
Ctgene under investigation−Ctendogenous control.
For expression analysis of genes involved in apoptosis,
total RNA from DeFew cells, silenced or not for IBTKα,
was analysed by Real-time PCR using RT2 Proﬁler PCR
Array-Human Apoptosis (Qiagen). Difference in gene
expression was considered signiﬁcant for more 2-folds
up-regulation or down-regulation[38]. We did not con-
sider genes with Ct values ranging from 30 to 40 in
shCTRL cells. The primers used for IBTKα, LPL, CD38,
ZAP70, and TNFα genes are listed in Supplementary
Table 2.
Protein extracts and western blotting
CLL samples were processed for Western blotting
analysis as previously described36. Brieﬂy, cells were lysed
in RIPA buffer, containing 1% NP-40, 10 mM Tris-HCl,
150mM NaCl, 0,5% Na-deoxycholate and 1mM EDTA,
supplemented with the protease inhibitor cocktail (com-
plete-mini EDTA-free tablets—Roche) on ice for 30min.
Lysates were clariﬁed by 30 min-centrifugation at
14,000xg, at 4 °C. Western blotting was performed by
suspending protein aliquots in loading buffer (Thermo
Fisher Scientiﬁc), resolved on Novex® NuPAGE® SDS-
PAGE Precast Bis-Tris Gels 4 to 12%, transferred to
PolyVinylidene-DiFluoride membrane (Millipore,
Bedford, MA, USA), and incubated with primary
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antibodies followed by incubation with horseradish-
peroxidase-linked mouse or rabbit IgG (1:2000)
(GE Healthcare Amersham, Little Chalfont, UK) in PBS
containing 5% non-fat dry milk (Bio-Rad Laboratories).
Proteins were detected by chemiluminescence using the
Immobilon Western Chemiluminescent HRP substrate
(Millipore). Primary antibodies were purchased from
Thermo Fisher Scientiﬁc (anti-IBtkα, PA5-24224) and
Cell Signalling (anti- β-Actin, #3700S).
Cell proliferation assay
DeFew cells, stably silenced or not for IBTKα by RNA
interference, were suspended in RPMI 1640 and 5 replicates
were plated in 96-wells microtiter plates at the concentra-
tion of 1× 104 cells/100 µl/well. Ten µl of Presto-blue cell
viability reagent (Thermo Fisher Scientiﬁc) was added to
each well at 10% ﬁnal concentration. PrestoBlue reagent is
soluble, non-toxic and quickly reduced by metabolically
active cells, providing a quantitative measure of viability and
cytotoxicity. Absorbance relative to reagent reduction by
cells was measured by optical density at different time
points in order to obtain growth kinetics of the cells.
Optical absorbance was measured at 570 and 600 nm, and
reads were normalised to 600 nm. The read at time 0 (T0)
was performed after 10min of incubation and cell
proliferation was monitored for 48 h.
Propidium iodide assay
Propidium iodide (PI) incorporation was performed as
previously described37. Brieﬂy, shIBTKα-transduced and
shCTRL-transduced DeFew cells (3× 105) were cen-
trifuged, and pellets were suspended in ﬂuorochrome
solution (0.1% sodium citrate, 0.1% Triton X-100, 50 mg/l
PI, in deionized water). After 60 min-incubation at 4 °C,
cells were analysed using Accury C6 Flow cytometer
(Becton Dickinson).
Flow cytometry
Intracellular IBtkα protein was detected by ﬂow
cytometry upon cell staining with anti-IBtkα antibody
(Novus NBP1-88512). Brieﬂy, cells were washed with PBS,
ﬁxed with 4% Paraformaldehyde, permeabilized with
permeabilization buffer (Becton Dickinson Biosciences),
washed with PBS and incubated with primary antibody
for 30 min at 4 °C. After washing, cells were incubated
with anti-rabbit-APC antibody (SouthernBiotech 4050-
11S) for 30 min at 4 °C, and analysed using Accury C6
Flow cytometer (Becton Dickinson).
Annexin-V assay
Annexin-V assay was performed as previously
described37. Brieﬂy, shIBTKα-transduced and shCTRL-
transduced MEC-1 cells were treated with 25 or 50 µM
Fludarabine, or left untreated, for 72 h. At the end of
treatments, cells were harvested, washed 2 times with 1x
PBS, and suspended by gently vortexing in 100 µl of
Annexin-V binding buffer (BD Pharmingen) containing
5 µl of Annexin-V-APC (Becton Dickinson Biosciences),
for 15 min at room temperature. After incubation, 400 µl
of binding buffer was added and samples were analysed
using Accury C6 Flow cytometer (Becton Dickinson). The
binding of Annexin-V-APC was evaluated only for GFP-
positive cells, as control of shRNA transduction.
Statistical analysis
Statistical analysis was performed by Mann–Whitney test
applying 95% conﬁdence intervals and using a two-tailed
p-value, with GraphPad Prism 6 software. Differences were
considered signiﬁcant with p-value less than 0.05.
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